Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study

Bendamustine demonstrated synergistic efficacy with bortezomib against multiple myeloma (MM) cells in vitro and seems an effective treatment for relapsed-refractory MM (rrMM). This phase II study evaluated bendamustine plus bortezomib and dexamethasone (BVD) administered over six 28-day cycles and t...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Offidani, M, Corvatta, L, Maracci, L, Liberati, A M, Ballanti, S, Attolico, I, Caraffa, P, Alesiani, F, Caravita di Toritto, T, Gentili, S, Tosi, P, Brunori, M, Derudas, D, Ledda, A, Gozzetti, A, Cellini, C, Malerba, L, Mele, A, Andriani, A, Galimberti, S, Mondello, P, Pulini, S, Coppetelli, U, Fraticelli, P, Olivieri, A, Leoni, P
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2013
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3880441/
https://ncbi.nlm.nih.gov/pubmed/24270324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2013.58
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky